• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » Suvorexant prevents delirium [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts, Android, or Stitcher.

Suvorexant prevents delirium [60 Sec Psych]

September 19, 2020

We often worry about sleep meds in the medically ill, and there’s plenty of cause to: falls, respiratory suppression, and confusion. On the other hand, sleep disruption is a major risk factor for delirium, and there’s growing evidence that some sleep meds – ramelteon, melatonin, but not the benzos or z-hypnotics -  can prevent this sequale of surgery and major medical illness. This study adds the orexin antagonist Suvorexant/Bellsomra to that list. [Study Link]


Published On: 9/16/2020


Duration: 2 minutes, 55 seconds


Transcript: 

We often worry about sleep meds in the medically ill, and there’s plenty of cause to: falls, respiratory suppression, and confusion. On the other hand, sleep disruption is a major risk factor for delirium, and there’s growing evidence that some sleep meds – ramelteon, melatonin, but not the benzos or z-hypnotics - can prevent this sequale of surgery and major medical illness. This study adds the orexin antagonist Suvorexant/Bellsomra to that list.

It was a metaanalysis of 7 trials – 3 were the classic prospective RCTs, 4 were retrospective case-control studies. Generally they compared patients who took Suvorexant with others in the hospital or ICU setting. Overall, treatment with Suvorexant reduced delirium by 30%, and delayed the time to delirium with a moderate effect size of 0.44. The limitation was the inclusion of retrospective studies, although the effect was a little larger in the prospective studies and all studies had a positive effect. Also the total size was small for a meta-analysis, 487 patients. The analysis received no industry funding.

Suvorexant may reduce delirium by improving sleep or by blocking orexin, levels of which are elevated in delirium and are associated with increased parasympathetic and inflammatory activity.

Suvorexant, its cousin lemborexant, ramelteon, melatonin, and low-dose doxepin are the only sleep meds that aren’t considered potentially inappropriate in the elderly by the Beers Criteria. So far, 3 of those Suvorexant ramelteon and melatonin, have evidence to prevent delirium. We’ll have more coverage of the other two - ramelteon and melatonin – in our October issue.

Got feedback? Take the podcast survey.
Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop For Total Access

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto22709844.jpg
    General Psychiatry

    Psychopharm Commandment #10: Don’t Fear these Meds

    Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.